diarylquinoline tibotec medical compound 207 (Tibotec Pharmaceuticals)
90
Structured Review
Tibotec Pharmaceuticals
diarylquinoline tibotec medical compound 207
Diarylquinoline Tibotec Medical Compound 207, supplied by Tibotec Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+207+(diarylquinoline)/tmc207/pm19925960-110-1-2
Average 90 stars, based on 1 article reviews
Diarylquinoline Tibotec Medical Compound 207, supplied by Tibotec Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/compound+207+(diarylquinoline)/tmc207/pm19925960-110-1-2
Average 90 stars, based on 1 article reviews
diarylquinoline tibotec medical compound 207 - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
other:Article Title: Pediatric TB: issues related to current and future treatment options. Article Snippet: From a TB control point of view, the treatment of children is not considered a priority in endemic areas, as they rarely transmit disease and contribute little to the maintenance of the TB epidemic.. Of the estimated 8.3 million new TB cases diagnosed in 2000, 884,019 (11%) were children and it is estimated that those under 15 years of age contributed 15–20% of the disease burden in endemic areas [1].. However, accurate quantification of the global pediatric TB epidemic is currently impossible, given the diagnostic difficulties and poor reporting systems in resourcelimited settings that carry the brunt of the disease burden [2,3]. Activity Assay:Article Title: Multidrug- and extensively drug-resistant tuberculosis in Africa and South America: epidemiology, diagnosis and management in adults and children. Article Snippet: Africa, and mainly sub-Saharan Africa, have a high incidence of tuberculosis (TB) and the highest prevalence of human immunodeficiency virus (HIV) in the world.. In addition, Africa is experiencing an increase in multidrug-resistant TB (MDR-TB) (ie, resistance to at least isoniazid [INH] and rifampicin [RMP]), with 14% of the global burden of new MDR-TB cases occurring in Africa, and early warnings of extensively drug-resistant TB (XDR-TB; ie, MDR plus resistance to the fluoroquinolones and 1 of 3 second-line injectable agents), especially in South Africa.. Until recently, many African countries treated TB with a 2-month 4-drug intensive Phase including INH and RMP, and a 7-month continuation Phase of INH and |